Effect of perioperative intravenous injection of vitamin C on pain after total knee replacement

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300068511

Enrollment

Unknown

Registered

2023-02-21

Start date

2023-02-24

Completion date

Unknown

Last updated

2023-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

control group:During the operation, intravenous injection of 3g vitamin c dissolved in 500ml normal saline was given after anesthesia induction, and the same strategy was given 24h and 48h after surge

experiment group:Intraoperative 500ml normal saline was given intravenously after induction of anesthesia, and the same strategy was given 24h and 48h after surgery.

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. The patient meets American Society of Anesthesiologists Classification Status I-III 2. Patients who underwent primary unilateral total knee replacement in West China Hospital of Sichuan University 3. The patient was diagnosed with knee OA

Exclusion criteria

Exclusion criteria: 2.1 Patients with increased risk of adverse events due to corticosteroid use in non-osteoarthritis patients, 2.2 Patients Patients with long-term use of vitamin c therapy, 2.3 Revision of primary bilateral knee or total knee; 2.4 Patients with heart, liver, lung or kidney disease, 2.5 Knee flexion deformity =30°; Varus-valgus deformity =30°; 2.6 History of knee surgery (arthroscopic and open surgery); 2.7 History of knee infection; 2.8 History of excessive alcohol consumption; 2.9 Mental illness; Cognitive impairment; Patients who regularly use psychotropic drugs or are addicted to opioids 2.10 Uncontrolled hypertension 2.11 Diarrhea 2.12 Anesthesia dependence 2.13 Neuromuscular disease was diagnosed 2.14 Thrombotic events (myocardial infarction, cerebrovascular accident, deep vein thrombosis or pulmonary embolism) 2.15 Inability to communicate verbally 2.16 Patients with allergies and contraindications to opioids, celecoxib and vitamin c 2.17 Patients who received any analgesic (e.g., NSaids, opioids or paracetamol) on a regular basis or within three days prior to scheduled surgery 2.18 Patients with renal insufficiency and high creatinine; 2.19 Refusal of informed consent

Design outcomes

Primary

Measure	Time frame
VAS;Total number of analgesia required;Use time of the first analgesic;Analgesic dosage;IL-6 level;IL-10 level;CRP level;	—

Secondary

Measure	Time frame
Movement score;Range of motion;Postoperative recovery quality;Complication;	—

Countries

china

Contacts

Public ContactKang Pengde

West China Hospital, Sichuan University

kangpd@163.com+86 18980601953

Outcome results